Semaglutide studies
8,508 journal papers mention Semaglutide in the title or abstract. Here are the most cited, the latest, and a few facts about the literature.
Studies range from laboratory work to clinical trials. A paper listed here is not an endorsement and says nothing about whether Semaglutide is safe, effective or approved for any use.
- Papers
- 8,508
- 6,959 articles, 1,549 reviews
- Earliest paper
- 2004
- Most papers in 2026 (2,732)
- Open access
- 64%
- free to read somewhere
- Reviews
- 18%
- of all papers listed
What kind of studies
Of 5,834 papers in PubMed that mention Semaglutide in the title or abstract, by the study type PubMed records. Categories overlap, so they do not add up to the total.
- Randomized controlled trials313
- Other clinical trials32
- Meta-analyses and systematic reviews427
- Other reviews1,739
- Case reports312
- Animal studies only278
- Studies in humans3,314
Study types are tags assigned by publishers and PubMed indexers; very new papers are often not tagged yet, and a tag is not a quality rating. Retracted papers are excluded. Source: PubMed (NCBI).
Registered clinical studies
Studies on ClinicalTrials.gov that mention Semaglutide in their intervention details. A registration says a study is planned or running, not what it found.
- Registered
- 796
- Completed
- 353
- Ongoing or planned
- 373
- Phase 1
- 127
- Phase 2
- 153
- Phase 3
- 185
- Comparing Different Medication Regimens to Maintaining Weight Loss Among Adults With Obesity Using GLP-1s
NCT07832084Not yet recruitingPhase 4started 2026-12
- Focusing on the Menopausal Transition to Improve Mid-Life Women's Health
NCT06975111RecruitingPhase 2 / Phase 3started 2026-03-01
- Brain and Obesity Longitudinal Development: Neurobiological Mechanisms of Semaglutide Treatment of Adolescent Obesity
NCT07911046Not yet recruitingstarted 2027-03
- Research Study to Look at How Well Semaglutide Works in People Living With Heart Failure, Obesity and Type 2 Diabetes
NCT04916470CompletedPhase 3started 2021-06-15
- Changes in Body Composition Following Pharmacological Treatment for Obesity.
NCT07908940Enrolling by invitationstarted 2025-09-01
The five most recently updated studies. See all 796 on ClinicalTrials.gov. Source: ClinicalTrials.gov (U.S. National Library of Medicine). Studies are found by the compound's name, so a few may be about something else.
Papers per year
2004 to 2026, peak 2,732 papers in a year. The latest year may still be incomplete.
Where it is published
- Diabetes492 papers
- Diabetes Obesity and Metabolism358 papers
- Cureus164 papers
- European Heart Journal158 papers
- Journal of the Endocrine Society117 papers
The papers
Most citedName in the title
- The Discovery and Development of Liraglutide and Semaglutide
Lotte Bjerre Knudsen, Jesper F. Lau · Frontiers in Endocrinology · 2019
ReviewOpen access · CC BY971 citationsRead the open copy →
LatestName in title or abstract
- Efficacy and safety of semaglutide versus placebo in adults with overweight or obesity without diabetes: updated meta-analysis of randomized trials
Rida Wajid, Ravi Kumar, Misbah Muneer et al. · Journal of Diabetes & Metabolic Disorders · 2026
Review
- EMERGING PHARMACOLOGICAL STRATEGIES IN OBESITY: FROM GLP-1 AGONISTS THROUGH TRIPLE INCRETIN THERAPY TO AMYLIN ANALOGS – NARRATIVE REVIEW
Dagmara Laufer, Olga Klimczak, Filip Chodań et al. · Archiv Euromedica · 2026
ReviewOpen accessRead the open copy →
- Switching between semaglutide and tirzepatide in obesity Management: an expert-consensus framework for approximate clinical Efficacy-matched switching doses
Eyal Schwartzberg, Erez Berman, Segev Shani et al. · Expert Opinion on Pharmacotherapy · 2026
ReviewOpen access · CC BY-NC-NDRead the open copy →
- Comparative Effects of Pharmacological Treatment on Heart Failure with Mildly Reduced or Preserved Ejection Fraction: A Systematic Review and Network Meta-analysis of Randomized Controlled Trials
Jingyi Zhang, 王永健, Jinjin Li et al. · Drugs · 2026
Systematic review
- Efficacy and Safety of CagriSema in Type 2 Diabetes: A Dose‐ and Comparator‐Specific Systematic Review and Bayesian Meta‐Analysis
Chia Siang Kow, Abdullah Faiz Zaihan, Dinesh Sangarran Ramachandram et al. · Diabetes Obesity and Metabolism · 2026
ReviewOpen access · CC BYRead the open copy →
- What Is the Role of GLP-1 Receptor Agonists in the Treatment of MASLD: A Narrative Review
Sweera A. Qari, Kay Samuel, Jonathan Andrew Fallowfield et al. · Livers · 2026
ReviewOpen access · CC BYRead the open copy →
- GLP‐1–Based Therapy in Type 1 Diabetes: Balancing Efficacy, Safety, and Patient Selection
Thales Rossatto, Ricardo de Andrade Oliveira, Andréia Machado Cardoso · Diabetes Obesity and Metabolism · 2026
ReviewOpen access · CC BYRead the open copy →
- Beyond glycemic control: emerging therapeutic applications of GLP-1 receptor agonists: a comprehensive narrative review
Nidhi Srivastava, Siddhant Mehrotra, Shubham Biswas et al. · International Journal of Basic & Clinical Pharmacology · 2026
ReviewOpen access · CC BY-NC-NDRead the open copy →
Each list shows up to 40 papers.See all 8,508 on OpenAlex. Source: OpenAlex (CC0), journal articles and reviews with a DOI, retractions excluded, refreshed weekly, last 4 Nov 2026, 08:31 UTC. Papers are listed by their metadata only; follow the links to read them. A license shown on an open copy is the license the publisher or repository states for that copy.